



**SONIC
HEALTHCARE
LIMITED**

15 June 2015

SONIC HEALTHCARE EXPANDS IN SWITZERLAND

Sonic Healthcare Limited ("Sonic") (SHL.AX) is pleased to announce that it has signed binding agreements to acquire the Swiss medical laboratory group, Medisupport S.A.

Medisupport is one of the market leaders in Switzerland, with operations in 10 cities across the German and French speaking regions of the country, including Geneva, Lucerne, Berne, Lausanne and Zurich. Medisupport has annual revenues of around CHF 160 million, employs more than 700 staff and has built impressive, cutting-edge capabilities in medical and scientific quality, eHealth solutions and personalised service to its customers. Operating one of Switzerland's largest genetics and next-generation sequencing laboratories, Medisupport will add value to Sonic's capabilities in this burgeoning field of medicine, including the in-house development of genetic tests.

The transaction is expected to complete in July 2015. Medisupport's founders and partners will become shareholders of Sonic and will continue in their executive roles on a long-term basis.

Sonic's CEO, Dr Colin Goldschmidt said: "Our further expansion in the Swiss laboratory market is a logical step for Sonic Healthcare, as we move to strengthen our position in Europe. We are excited to partner with a laboratory group of such high quality and which shares our culture and values in such a remarkably similar way. Together with our already-strong Zurich-based operations, Sonic moves into the clear number one position in the Swiss laboratory market, providing an excellent platform for future growth and service enhancement. Medisupport's strong capabilities in many laboratory disciplines, including genetics, will provide valuable synergy enhancing opportunities for Sonic in Europe and around the world. We are delighted to welcome the medical, laboratory and management staff of Medisupport to Sonic's European and worldwide team".

The (cash and debt free) purchase consideration represents a prospective (FY2016) EBITDA multiple of approximately 8 times, pre-synergies. The consideration will comprise CHF 277 million in cash, funded from Sonic's debt facilities, and the issue of Sonic Healthcare ordinary shares¹. The transaction, inclusive of share issue, is expected to be accretive to Sonic's earnings per share by approximately 8% initially, and this is expected to increase further on realisation of synergies with Sonic's existing Swiss and European businesses. The return on invested capital (ROIC) will be accretive in year one.

For further information regarding this announcement, please contact:

Paul Alexander

Deputy CFO and Company Secretary

Sonic Healthcare

Telephone: +61 2 9855 5404

Email: pauljalex@bigpond.com

¹ The minimum number of Sonic ordinary shares to be issued is 3,559,452. The number of Sonic shares to be issued may increase if the volume weighted average price of trading of Sonic shares over the five trading days commencing on the thirteenth trading day after the record date of Sonic's 2015 final dividend, or, in the unlikely circumstance that closing has not occurred by that time, the volume weighted average trading price over the five trading days preceding closing, is less than A\$ 19.62 per share. The shares will be issued on the 18th trading day after the record date for Sonic's 2015 final dividend, or if closing has not taken place prior to that date, at closing. The shares will not be eligible for Sonic's 2015 final dividend, and will be subject to a 12 month escrow. Shareholder approval is not required for the issue of the shares.